<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663024</url>
  </required_header>
  <id_info>
    <org_study_id>GC1111B_P2</org_study_id>
    <nct_id>NCT02663024</nct_id>
  </id_info>
  <brief_title>Study of Idursulfase-beta (GC1111) in Hunter Syndrome</brief_title>
  <official_title>Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Idursulfase-beta (GC1111) in Hunter Syndrome (Mucopolysaccharidosis II) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of three doses of GC1111 in patients with Hunter
      Syndrome. Participants will be randomized to one of three doses of GC1111 or comparator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, active-controlled, dose-ranging study, where patient will
      receive one of the three doses of GC1111 (0.5 mg/kg, 1.0 mg/kg, and 1.5 mg/kg) or ELAPRASE
      0.5 mg/kg. Approximately 20 patients will be administrated each study drug once every week as
      an iv infusion for 24 weeks. Efficacy of GC1111 will be evaluated in Six-Minute Walk Test
      (6MWT), urine Glycosaminoglycans(uGAG), liver and spleen volume, percent predicted Forced
      Vital Capacity(FVC), and cardiac size and function. Also immunogenicity, Pharmacokinetics(PK)
      and safety will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in urinary GAG(Glycosaminoglycans) at Week 25</measure>
    <time_frame>Baseline to Week 25</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urinary GAG at Week 25</measure>
    <time_frame>Baseline to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Six Minute Walk Test at Week 25</measure>
    <time_frame>Baseline to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Six Minute Walk Test at Week 25</measure>
    <time_frame>Baseline to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Liver volume at Week 25</measure>
    <time_frame>Baseline to Week 25</time_frame>
    <description>Liver volume measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Liver volume at Week 25</measure>
    <time_frame>Baseline to Week 25</time_frame>
    <description>Liver volume measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Spleen volume at Week 25</measure>
    <time_frame>Baseline to Week 25</time_frame>
    <description>Spleen volume measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Spleen volume at Week 25</measure>
    <time_frame>Baseline to Week 25</time_frame>
    <description>Spleen volume measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Serious Adverse Events</measure>
    <time_frame>Baseline to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety changes from baseline in clinical laboratory tests, physical examination and vital signs</measure>
    <time_frame>Baseline to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Baseline to Week 25</time_frame>
    <description>anti-drug-antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile - Area under the serum concentration time curve (AUClast)</measure>
    <time_frame>1 and 17 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile - Maximum observed peak plasma concentration (Cmax)</measure>
    <time_frame>1 and 17 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile - Time at which Cmax is observed (Tmax)</measure>
    <time_frame>1 and 17 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5mg/kg, iv, weekly infusion of idursulfase for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>idursulfase beta</intervention_name>
    <description>IV, weekly infusion for 24 weeks</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>GC1111</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>idursulfase</intervention_name>
    <description>0.5 mg/kg, iv, weekly infusion for 24 weeks</description>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>Elaprase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients between 5 and 35 years of age

          -  Informed consent form signed

          -  Patients diagnosed with hunter syndrome

          -  Previously untreated with an enzyme replacement therapy

        Exclusion Criteria:

          -  History of tracheostomy, bone marrow transplant, or cord blood transplant

          -  Treatment with another investigational product within 30 days prior to the start of
             study drug

          -  Known hypersensitivity of any of the ingredients of study drug

          -  Patient with severe hunter syndrome who cannot perform 6MWT

          -  Female patients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sangmi Kang</last_name>
    <phone>82-31-260-1957</phone>
    <email>sm6220@greencross.com</email>
  </overall_contact>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2016</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

